GlobalData on MSN4d
Sanofi’s Sarclisa combo approved in China for multiple myelomaSanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...
Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...
Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...
Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...
The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
The Union Budget 2025-26 introduces key healthcare measures, including the exemption of 36 life-saving drugs from Basic ...
China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...
BoXer incorporates the anti-myeloma drug bortezomib, an agent known to stimulate net bone formation while effectively killing tumor cells. BoXer releases this 'payload' locally at the site of bone ...
BoXer incorporates the anti-myeloma drug bortezomib, an agent known to stimulate net bone formation while effectively killing tumor cells. BoXer releases this "payload" locally at the site of bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback